August 2, 2012 — The Heart Rhythm Society (HRS) and the American College of Cardiology Foundation (ACCF) has released the HRS/ACCF Expert Consensus Statement on Pacemaker Device and Mode Selection, the first of its kind to specifically address pacemaker device and mode selection.


Interventional procedures are growing rapidly and becoming more specialized in diverse areas of care.  In the next decade, the number of people living in the United States who have heart conditions is expected to continue to increase, as is the elderly segment of the population and the number of people with chronic disorders such as cardiovascular disease cancer, diabetes and obesity.[1] Driven by these trends and enabled by breakthrough technology allowing new, less invasive approaches to therapy, hospitals are looking at the interventional suite as a strategic area of investment. 

July 31, 2012 — Bracco Diagnostics Inc., the U.S.-based company of the Bracco Group, announced that the U.S. Food and Drug Administration (FDA) has approved the use of MultiHance (gadobenate dimeglumine) injection, 529 mg/mL, in magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease.

July 31, 2012 — Boston Scientific Corp. has received CE mark approval for use of its Ingenio and Advantio pacemakers in patients in need of a magnetic resonance image (MRI).

ICD, CRT battery life

In the coming years, the continued growth and aging of our population will both increase the demand for treatment with implantable cardiac rhythm devices and stretch our ability to pay for care. Toward solving this, we must continue to improve clinical quality not just to provide a better future for patients, but to control costs so that we are able to meet the increased demand.

July 31, 2012 – Diagnostic and Interventional Cardiology (DAIC) has applied for business publication membership in BPA Worldwide, which will track DAIC's circulation. The tracking includes business/distribution, demographics and geographic coverage. The magazine will have 12 months to complete its initial circulation audit. 

July 31, 2012 — Siemens Healthcare announced that the Magnetom Spectra 3.0T magnetic resonance imaging (MRI) system has received clearance from the U.S. Food and Drug Administration (FDA).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now